No description available.

Les cannabinoides (CBs) et plus spécifiquement les agonistes des récepteurs CB2 ontdémontré leurs propriétés analgésiques, sans effet psychotrope comparés auxagonistes CB1. Les CBs sont généralement des composés lipophiles et non “drug-like”présentant une faible biodisponibilité. Afin d’évaluer de nouveaux CB2 agonistesd’origine synthétique développés par notre laboratoire, sur des modèles in vivo dedouleur neuropathique, une stratégie de formulation précoce a été mise au point et apermis le développement de quatre systèmes de délivrance d’actif. Une étudepharmacologique d’efficacité a été conduite avec notre tête de série MDA7, formulédans des complexes d’inclusion avec des cyclodextrines (CDs), des liposomes et unesolution micellaire administrés par voie parentérale. Le concept à base de CDs adémontré une plus forte activité anti nociceptive. Une étude de compréhension dumécanisme d’inclusion de MDA7 dans le complexe supramoléculaire formé avec lesCDs a été menée. Des systèmes auto-émulsionnables (SEDDS) ont également étéutilisés pour une administration orale afin d’étudier le profile pharmacocinétique deMDA7. Des nanocapsules (NCs) polymériques et cationiques ont également été développéesafin de stabiliser un phytocannabinoide, CB2, en vue d’une administration in vivo. Desétudes pour caractériser et évaluer l’influence des paramètres affectant la formation desNCs préparées par nanoprécipitation ont été conduites. Nous avons étudié lapropension des NCs développées à former des interactions ioniques avec desmacrocycles anioniques tels que les sulfobutylether-β-cyclodextrines ou, desinteractions électrostatiques avec les cucurbit[n]urils / Cannabinoids (CBs) and particularly CB2 agonists have been shown to reduce pain andinflammation without eliciting any apparent psychotropic effect conversely to CB1agonist compounds. CBs candidates are usually lipophilic non drug-like compoundswith poor bioavailability. To serve the purpose of evaluating new synthetic CB2 agonistsdeveloped by our group, on in vivo neuropathic pain models, an enabling formulationstrategy has been set up and four Drug Delivery Systems (DDS) developed. Forparenteral administration, cyclodextrin (CD)-based inclusion complexes, liposomes andsurfactants/co-solvents micellar solution have been investigated whereas Self-Emulsifying DDS (SEDDS) was selected for oral administration. A pharmacologicalstudy conducted with lead compound MDA7, formulated in CD-based DDS resulted inthe higher antinociceptive activity. A comprehensive study of the inclusion mechanismof MDA7 in the CD supramolecular complexes prepared was carried out. MDA7pharmacokinetic profile was also generated formulated in micellar solution and SEDDS.Besides, cationic polymeric nanocapsules (NCs) have been designed to serve as aprotective DDS for oral administration of a dietary phytocannabinoid CB2 agonist.Studies were undertaken to characterize and evaluate the influence of differentparameters on NCs formation prepared by nanoprecipitation. The cationic NCsdeveloped have been explored for their property to yield proportion of counterioniccondensation in the presence of macrocycles bearing anionic groups such assulfobutylether-beta-cyclodextrin or to form electrostatic interactions/host-guestcomplexion with cucurbit[n]uril.

Cannabinoids (CBs) and particularly CB2 agonists have been shown to reduce pain andinflammation without eliciting any apparent psychotropic effect conversely to CB1agonist compounds. CBs candidates are usually lipophilic non drug-like compoundswith poor bioavailability. To serve the purpose of evaluating new synthetic CB2 agonistsdeveloped by our group, on in vivo neuropathic pain models, an enabling formulationstrategy has been set up and four Drug Delivery Systems (DDS) developed. Forparenteral administration, cyclodextrin (CD)-based inclusion complexes, liposomes andsurfactants/co-solvents micellar solution have been investigated whereas Self-Emulsifying DDS (SEDDS) was selected for oral administration. A pharmacologicalstudy conducted with lead compound MDA7, formulated in CD-based DDS resulted inthe higher antinociceptive activity. A comprehensive study of the inclusion mechanismof MDA7 in the CD supramolecular complexes prepared was carried out. MDA7pharmacokinetic profile was also generated formulated in micellar solution and SEDDS.Besides, cationic polymeric nanocapsules (NCs) have been designed to serve as aprotective DDS for oral administration of a dietary phytocannabinoid CB2 agonist.Studies were undertaken to characterize and evaluate the influence of differentparameters on NCs formation prepared by nanoprecipitation. The cationic NCsdeveloped have been explored for their property to yield proportion of counterioniccondensation in the presence of macrocycles bearing anionic groups such assulfobutylether-beta-cyclodextrin or to form electrostatic interactions/host-guestcomplexion with cucurbit[n]uril.